← All rollout articles

Pharma manufacturer: quality systems and validated releases

Problem

Quality and manufacturing systems were modernizing, but validation lag turned every release into a paper marathon. IT velocity and QA confidence moved in opposite directions.

Constraints

GxP expectations, audit trail immutability, and supplier audits from both customers and regulators. “DevOps” language did not map cleanly to existing SOP language.

Approach

We reframed CI/CD as a controlled automation SOP: defined roles, segregation of duties, and evidence generated as a byproduct—not assembled after the fact. Risk-based testing focused on patient impact and data integrity—not every screen pixel every time.

Rollout

Pilot systems with lower classification first; then expand patterns through a validation playbook library. Independent QA reviewed evidence packs, not every commit by default.

Risks mitigated

• Shadow releases: single pipeline truth with signed artifacts
• Human transcription errors: automated trace matrices where feasible
• Cultural rejection: bilingual mapping from old SOP steps to new automated checks

Outcomes (illustrative)

Lead time from “code ready” to “validated release” decreased while audit findings related to release documentation decreased compared to the prior three-year baseline.

Lessons

Regulated environments don’t hate speed—they hate unowned risk. Ownership clarity unlocked automation.